Market Overview

Moderna Analyst Downgrades COVID-19 Vaccine Developer, Sees 'Changing Competitive Environment'

Share:
Moderna Analyst Downgrades COVID-19 Vaccine Developer, Sees 'Changing Competitive Environment'

Competitive pressure could impair Moderna Inc's (NASDAQ: MRNA) ability to take advantage of its strong position in the coronavirus vaccine race, according to an analyst at SVB Leerink.

The Moderna Analyst: Mani Foroohar downgraded Moderna from Market Perform to Underperform and lowered the price target from $58 to $41. 

The analyst initiated coverage of the stock in July at Market Perform with a $65 price target.

The Moderna Thesis: SVB Leerink's newly bearish stance is due to Moderna ceding its lead in the clinical development of its mRNA-1273 vaccine for SARS-CoV-2; rivals pocketing multiple large COVID-19 vaccine contracts; and the risk of reduced end user demand due to fears that vaccines could be rushed to the market under emergency use authorization, Foroohar said in a Tuesday downgrade note. 

These factors make a durable market with oligopoly pricing unlikely, the analyst said. 

The probability of Moderna securing emergency use authorization in the fourth quarter is high, but the "speed to market" has fallen behind that of competitors, he said.

Even with aggressive assumptions, there is no avenue to confidently predict beats versus 2021 estimates, Foroohar said.

Longer-term estimates have started to rationalize from the highs this summer but are still inflated, the analyst said. 

The rerating of consensus estimates is being accompanied by heightened headline risk, with increasing media scrutiny of aggressive insider selling, he said. 

"As the Street digests the changing competitive environment, we believe shares will continue to face pressure ahead of presumptive EUA and first commercial sales this winter."

SVB Leerink sees Moderna shares underperforming amid competitor dataset releases, contract wins and commercial launches, as its valuation comes to reflect secular challenges in the key end market.

MRNA Price Action: At last check, Moderna shares were slipping by 7.68% to $57.79. 

Related Links:

The Week Ahead In Biotech: Focus On Mallinckrodt FDA Decision, Conference Presentations

Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates

Latest Ratings for MRNA

DateFirmActionFromTo
Sep 2020SVB LeerinkDowngradesMarket PerformUnderperform
Aug 2020SVB LeerinkMaintainsMarket Perform
Aug 2020SVB LeerinkMaintainsMarket Perform

View More Analyst Ratings for MRNA
View the Latest Analyst Ratings

 

Related Articles (MRNA)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Downgrades Health Care Price Target Analyst Ratings Movers Trading Ideas Best of Benzinga

Latest Ratings

StockFirmActionPT
DOWTruist SecuritiesMaintains55.0
SBUXJP MorganMaintains80.0
AAPLCitigroupMaintains125.0
BCDAAlliance Global PartnersInitiates Coverage On11.5
EURNJonesTradingInitiates Coverage On
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com